Excision: Excision BioTherapeutics Presents Data from HBV and HSV Programs at the ASGCT 2025 Annual Meeting

Poster presentation to demonstrate EBT-107's potential to reduce clinically-relevant biomarkers and HBV DNA integration toward functional remission of chronic hepatitis B Oral presentation to highlight significant reduction in HSC-1 viral load in the latent HSV-1 reservoir and near elimination of ocular viral shedding in a preclinical HSV-1 keratitis model, achieved through intravenous delivery of all-in-one AAV9 vectorsResidual HSV-1 DNA in the latent reservoir contained mutations and large genomic deletions, indicating effective disruption of the latent HSV-1 reservoirWATERTOWN, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc. ("Excision" or the "Company"), a biotechnology company developing CRISPR-based therapies to cure viral infectious diseases, today announced new data presentations from its preclinical programs, hepatitis B virus (HBV), EBT-107 and herpes simplex virus (HSV-1) keratitis, EBT-104 at the 2025 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking place May 13-17 in New Orleans, Louisiana.Chronic hepatitis B caused by infection of hepatitis B virus (HBV) is one of the most prevalent infectious diseases worldwide that lacks curative therapies. While existing antiviral and immunomodulator treatments slow progression of liver disease by reducing viral load, they fail to eliminate covalently closed circular DNA (cccDNA) that enables persistent viral infection. Excision's lead product candidate for the treatment of HBV infection, EBT-107, uses dual guide RNAs to excise large sections of viral DNA and effectively deactivate the virus."A series of in vitro and in vivo studies indicate our dual guide-RNA-mediated editing strategy eliminates intrahepatic HBV DNA levels and suppresses HBV DNA integration that may contribute to hepatocarcinogenesis," said Jennifer Gordon, Ph.D, Chief Scientific Officer of Excision. "We believe that these data further validate our HBV program and will help progress EBT-107 toward an anticipated ...Full story available on Benzinga.com